- Home
- AUTL vs INBX Comparison
AUTL vs INBX Comparison
Compare AUTL & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AUTL | INBX |
|---|---|---|
| Founded | 2014 | 2010 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 433.8M | 430.2M |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AUTL | INBX |
|---|---|---|
| Price | $1.39 | $72.36 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 2 |
| Target Price | ★ $8.33 | N/A |
| AVG Volume (30 Days) | ★ 2.7M | 218.5K |
| Earning Date | 11-12-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $51,128,000.00 | $1,400,000.00 |
| Revenue This Year | $672.42 | $563.00 |
| Revenue Next Year | $84.48 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 406.67 | N/A |
| 52 Week Low | $1.11 | $10.81 |
| 52 Week High | $2.70 | $94.57 |
Technical Indicators
Market Signals| Indicator | AUTL | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 37.52 | 41.77 |
| Support Level | $1.34 | $69.47 |
| Resistance Level | $1.97 | $76.47 |
| Average True Range (ATR) | 0.15 | 4.77 |
| MACD | -0.07 | -0.76 |
| Stochastic Oscillator | 5.48 | 20.55 |
Price Performance
Historical ComparisonAbout AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.